- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.02. | Samsung Biologics and LegoChem enter ADC development deal | ||
| 07.02. | NIH grants $9m for nicotine cessation drug development | ||
| 06.02. | Exicure and Bluejay sign hepatitis treatment development deal | ||
| 05.02. | Zuellig Pharma acquires Cialis and Alimta brands from Lilly | ||
| 02.02. | US FDA grants orphan drug status for Rznomics' HCC treatment | ||
| 01.02. | Sandoz launches Tyruko in Germany for treatment of adults with RRMS | ||
| 31.01. | US FDA grants ODD to NeoImmuneTech's NT-I7 for pancreatic cancer treatment | ||
| 30.01. | Oricell's OriCAR-017 application secures FDA IND clearance | ||
| 29.01. | EMA validates Pfizer-Astellas' bladder cancer therapy application for review | ||
| 26.01. | Entos opens GMP clinical manufacturing facility in US | ||
| 25.01. | UroGen submits new drug application to FDA for UGN-102 | ||
| 24.01. | BlueRock exercises option to license cell therapy candidate | ||
| 23.01. | ASTCT, ACCC and AACI launch initiative for CAR T therapy | ||
| 22.01. | Zokinvy gets Japanese approval for Progeria treatment | ||
| 19.01. | Kindeva Drug Delivery acquires Summit Biosciences | ||
| 18.01. | Eurofins Alphora completes Canadian biologics development facility | ||
| 17.01. | US FDA updates Sanofi's Dupixent label for atopic dermatitis | ||
| 16.01. | CARsgen's CT011 receives IND clearance from China's NMPA | ||
| 15.01. | GENESIS and Deciphera enter distribution agreement for Ripretinib | ||
| 12.01. | FDA grants two designations for GenFleet's drug candidate SLS009 | ||
| 11.01. | Fermion receives IND approval in China for pain relief drug FZ008-145 | ||
| 10.01. | AbbVie introduces Produodopa for advanced Parkinson's in EU | ||
| 09.01. | Simcha Therapeutics signs license agreement with Janssen for DR-18 | ||
| 08.01. | AOB Pharma, Maruho partner to develop B244 for inflammatory ailments | ||
| 05.01. | AGC Biologics to build new facility in Japan |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
